Sheppard Mullin Advised Signet Healthcare Partners in Growth Recapitalization Investment in PainTEQ

Sheppard Mullin advised Signet Healthcare Partners, a healthcare growth equity firm, in its co-led majority growth recapitalization of PainTEQ, a leading innovator in minimally invasive interventional spine care, alongside Windham Capital Partners. This recapitalization also included a new equity investment by MVolution Partners.

This strategic investment is set to accelerate PainTEQ's growth by funding clinical studies, advancing next-generation products and expanding its commercial operations in the U.S. PainTEQ's flagship product, the LinQ® SI joint implant is a proprietary, allograft-based and drill-less SI joint implant delivered via a minimally invasive posterior approach. To date, it has been used in over 14,000 procedures and is supported by strong clinical evidence, including the SECURE clinical trial.

The Sheppard Mullin deal team was led by partner Shon Glusky and special counsel Matt Silverstein.

Read the press release here.